LIVIVO - Search results -

Search results

Result 1 - 10 of total 34

Search options

Article ; Online: Single-Dose Ad26.COV2.S Vaccine-Room for Improvement.

Tehrani, Zahra Rikhtegaran / Sajadi, Mohammad M

JAMA network open

2021 Volume 4, Issue 11, Page(s) e2133012

MeSH term(s)	Ad26COVS1 ; Antibodies, Neutralizing ; COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2
Chemical Substances	Ad26COVS1 ; Antibodies, Neutralizing ; COVID-19 Vaccines
Language	English
Publishing date	2021-11-01
Publishing country	United States
Document type	Journal Article ; Comment
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2021.33012
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.

Tolbert, William D / Nguyen, Dung N / Tehrani, Zahra Rikhtegaran / Sajadi, Mohammad M / Pazgier, Marzena

mBio

2021 Volume 12, Issue 4, Page(s) e0127421

Abstract: ... lineage [M. M. Sajadi, A. Dashti, Z. R. Tehrani, W. D. Tolbert, et al., Cell 173:1783-1795.e14, 2018 ...

Abstract	The first step in HIV-1 entry is the attachment of the envelope (Env) trimer to target cell CD4. As such, the CD4-binding site (CD4bs) remains one of the few universally accessible sites for antibodies (Abs). We recently described a method of isolating Abs directly from the circulating plasma and described a panel of broadly neutralizing Abs (bnAbs) from an HIV-1 "elite neutralizer" referred to as patient N49 (N49 Ab lineage [M. M. Sajadi, A. Dashti, Z. R. Tehrani, W. D. Tolbert, et al., Cell 173:1783-1795.e14, 2018, https://doi.org/10.1016/j.cell.2018.03.061]). Here, we describe the molecular details of antigen recognition by N49P6, an Ab of the N49 lineage that recapitulates most of the neutralization breadth and potency of the donor's plasma IgG. Our studies done in the context of monomeric and trimeric antigens indicate that N49P6 combines many characteristics of known CD4bs-specific bnAbs with features that are unique to the N49 Ab lineage to achieve its remarkable neutralization breadth. These include the omission of the CD4 Phe
MeSH term(s)	Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/metabolism ; Binding Sites ; Binding Sites, Antibody ; CD4 Antigens/immunology ; CD4 Antigens/metabolism ; Crystallization ; Epitopes/chemistry ; Epitopes/metabolism ; HIV Antibodies/immunology ; HIV Antibodies/metabolism ; HIV Envelope Protein gp120/immunology ; HIV Envelope Protein gp120/metabolism ; HIV-1/immunology ; Host Microbial Interactions/immunology ; Humans ; Neutralization Tests ; Protein Multimerization
Chemical Substances	Antibodies, Neutralizing ; CD4 Antigens ; Epitopes ; HIV Antibodies ; HIV Envelope Protein gp120
Language	English
Publishing date	2021-07-20
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2557172-2
ISSN	2150-7511 ; 2161-2129
ISSN (online)	2150-7511
ISSN	2161-2129
DOI	10.1128/mBio.01274-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.

Saadat, Saman / Rikhtegaran Tehrani, Zahra / Logue, James / Newman, Michelle / Frieman, Matthew B / Harris, Anthony D / Sajadi, Mohammad M

JAMA

2021 Volume 325, Issue 14, Page(s) 1467–1469

MeSH term(s)	Adult ; Aged ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Asymptomatic Infections ; COVID-19/immunology ; COVID-19 Vaccines/administration & dosage ; COVID-19 Vaccines/immunology ; Female ; Health Personnel ; Humans ; Immunoglobulin G/blood ; Male ; Middle Aged ; SARS-CoV-2/immunology ; Vaccines, Synthetic/administration & dosage ; Vaccines, Synthetic/immunology ; mRNA Vaccines
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin G ; Vaccines, Synthetic
Language	English
Publishing date	2021-03-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	2958-0
ISSN	1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
ISSN (online)	1538-3598
ISSN	0254-9077 ; 0002-9955 ; 0098-7484
DOI	10.1001/jama.2021.3341
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.88: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer.

Atkinson, Ben / Abassi, Abdolrahim / Sajadi, Mohammad M / Tehrani, Zahra Rikhtegaran / Le, Nhut M / Chen, Hegang H / Sausville, Edward / DeVico, Anthony L / Lewis, George K / Fan, Xiaoxuan / Heredia, Alonso

AIDS research and human retroviruses

2023 Volume 39, Issue 9, Page(s) 475–481

Abstract: Non-small cell lung cancer (NSCLC) is the most fatal non-AIDS defining cancer in people living with HIV (PWH) on antiretroviral therapy (ART). Treatment of malignancies in PWH requires concomitant cancer therapy and ART, which can lead to potential drug- ... ...

Abstract	Non-small cell lung cancer (NSCLC) is the most fatal non-AIDS defining cancer in people living with HIV (PWH) on antiretroviral therapy (ART). Treatment of malignancies in PWH requires concomitant cancer therapy and ART, which can lead to potential drug-drug interactions (DDIs) and overlapping toxicities. In this study, we hypothesize that replacement of ART with HIV broadly neutralizing antibodies (bNAbs) during cancer chemotherapy (chemo) may maintain HIV suppression and tumor inhibition while minimizing DDIs and overlapping toxicities. We compared HIV suppression, tumor inhibition, and toxicity between conventional treatment (ART plus chemo) and a new modality (bNAbs plus chemo) in humanized mice. Humanized mice infected with HIV
MeSH term(s)	Humans ; Mice ; Animals ; HIV Infections/drug therapy ; Broadly Neutralizing Antibodies/pharmacology ; Broadly Neutralizing Antibodies/therapeutic use ; HIV Antibodies ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Antibodies, Neutralizing ; Lung Neoplasms/drug therapy ; HIV-1/genetics
Chemical Substances	Broadly Neutralizing Antibodies ; HIV Antibodies ; Antibodies, Neutralizing
Language	English
Publishing date	2023-05-05
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	639130-8
ISSN	1931-8405 ; 0889-2229
ISSN (online)	1931-8405
ISSN	0889-2229
DOI	10.1089/AID.2022.0181
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1928: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The silent presence of Mycoplasma hominis in patients with prostate cancer.

Saadat, Saman / Karami, Pezhman / Jafari, Mohammad / Kholoujini, Mahdi / Rikhtegaran Tehrani, Zahra / Mohammadi, Younes / Alikhani, Mohammad Yousef

Pathogens and disease

2020 Volume 78, Issue 7

Abstract: Background: Mycoplasma hominis, an opportunistic pathogen in human genitourinary tract, can cause chronic infection in the prostate. Intracellular survival of M. hominis leads to a prolonged presence in the host cells that can affect the cell's ... ...

Abstract	Background: Mycoplasma hominis, an opportunistic pathogen in human genitourinary tract, can cause chronic infection in the prostate. Intracellular survival of M. hominis leads to a prolonged presence in the host cells that can affect the cell's biological cycle. In the present study, we aimed to evaluate the frequency of M. hominis DNA in prostate tissue of Iranian patients with prostate cancer (PCa) in comparison to a control group with benign prostatic hyperplasia (BPH). Methods: This research was a retrospective case-control study using 61 archived formalin-fixed paraffin-embedded (FFPE) blocks of prostate tissue from patients with PCa and 70 FFPE blocks of patients with BPH. Real-time PCR, targeting two different genes, 16S rRNA and yidC, in the M. hominis genome was performed for all specimens. Results: Out of 61 blocks of prostate biopsy from patients with PCa, eight samples (13%) were positive for M. hominis, while the bacterium was not detected in any of the 70 blocks of patients with BPH (P value, 0.002). Conclusions: The high frequency of M. hominis in patients with PCa likely shows a hidden role of the organism in prostate cancer during its chronic, apparently silent and asymptomatic colonization in prostate.
MeSH term(s)	Asymptomatic Diseases ; Biopsy ; Case-Control Studies ; DNA, Bacterial ; Genes, Bacterial ; Humans ; Male ; Mycoplasma Infections/diagnosis ; Mycoplasma Infections/etiology ; Mycoplasma hominis/classification ; Mycoplasma hominis/genetics ; Opportunistic Infections/diagnosis ; Opportunistic Infections/etiology ; Prostatic Neoplasms/complications ; Prostatic Neoplasms/diagnosis ; Retrospective Studies
Chemical Substances	DNA, Bacterial
Keywords	covid19
Language	English
Publishing date	2020-09-17
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2049-632X
ISSN (online)	2049-632X
DOI	10.1093/femspd/ftaa037
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.

Sajadi, Mohammad M / Myers, Amber / Logue, James / Saadat, Saman / Shokatpour, Narjes / Quinn, James / Newman, Michelle / Deming, Meagan / Rikhtegaran Tehrani, Zahra / Magder, Laurence S / Karimi, Maryam / Abbasi, Abdolrahim / Shlyak, Mike / Baracco, Lauren / Frieman, Matthew B / Crotty, Shane / Harris, Anthony D

mSphere

2022 Volume 7, Issue 6, Page(s) e0027922

Abstract: With much of the world infected with or vaccinated against severe acute respiratory syndrome coronavirus 2 (commonly abbreviated SARS-CoV-2; abbreviated here SARS2), understanding the immune responses to the SARS2 spike (S) protein in different ... ...

Abstract	With much of the world infected with or vaccinated against severe acute respiratory syndrome coronavirus 2 (commonly abbreviated SARS-CoV-2; abbreviated here SARS2), understanding the immune responses to the SARS2 spike (S) protein in different situations is crucial to controlling the pandemic. We studied the clinical, systemic, mucosal, and cellular responses to two doses of SARS2 mRNA vaccines in 62 individuals with and without prior SARS2 infection that were divided into three groups based on antibody serostatus prior to vaccination and/or degree of disease symptoms among those with prior SARS2 infection: antibody negative (naive), low symptomatic, and symptomatic. Antibody negative were subjects who were antibody negative (i.e., those with no prior infection). Low symptomatic subjects were those who were antibody negative and had minimal or no symptoms at time of SARS2 infection. Symptomatic subjects were those who were antibody positive and symptomatic at time of SARS2 infection. All three groups were then studied when they received their SARS2 mRNA vaccines. In the previously SARS2-infected (based on antibody test) low symptomatic and symptomatic groups, reactogenic symptoms related to a recall response were elicited after the first vaccination. Anti-S trimer IgA and IgG titers, and neutralizing antibody titers, peaked after the 1st vaccination in the previously SARS2-infected groups and were significantly higher than for the SARS2 antibody-negative group in the plasma and nasal samples at most time points. Nasal and plasma IgA antibody responses were significantly higher in the low symptomatic group than in the symptomatic group at most time points. After the first vaccination, differences in cellular immunity were not evident between groups, but the activation-induced cell marker (AIM
MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19/prevention & control ; Reinfection ; Vaccination ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin A ; Immunoglobulin G
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin A ; Immunoglobulin G
Language	English
Publishing date	2022-11-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
ISSN	2379-5042
ISSN (online)	2379-5042
DOI	10.1128/msphere.00279-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement.

Liu, Qingbo / Zhang, Peng / Miao, Huiyi / Lin, Yin / Kwon, Young Do / Kwong, Peter D / Rikhtegaran-Tehrani, Zahra / Seaman, Michael S / DeVico, Anthony L / Sajadi, Mohammad M / Lusso, Paolo

Journal of virology

2021 Volume 95, Issue 12

Abstract: Broadly neutralizing antibodies (bNAbs) are the focus of increasing interest for human immunodeficiency virus type 1 (HIV-1) prevention and treatment. Although several bNAbs are already under clinical evaluation, the development of antibodies with even ... ...

Abstract	Broadly neutralizing antibodies (bNAbs) are the focus of increasing interest for human immunodeficiency virus type 1 (HIV-1) prevention and treatment. Although several bNAbs are already under clinical evaluation, the development of antibodies with even greater potency and breadth remains a priority. Recently, we reported a novel strategy for improving bNAbs against the CD4-binding site (CD4bs) of gp120 by engraftment of the elongated framework region 3 (FR3) from VRC03, which confers the ability to establish quaternary interactions with a second gp120 protomer. Here, we applied this strategy to a new series of anti-CD4bs bNAbs (N49 lineage) that already possess high potency and breadth. The resultant chimeric antibodies bound the HIV-1 envelope (Env) trimer with a higher affinity than their parental forms. Likewise, their neutralizing capacity against a global panel of HIV-1 Envs was also increased. The introduction of additional modifications further enhanced the neutralization potency. We also tried engrafting the elongated CDR1 of the heavy chain from bNAb 1-18, another highly potent quaternary-binding antibody, onto several VRC01-class bNAbs, but none of them was improved. These findings point to the highly selective requirements for the establishment of quaternary contact with the HIV-1 Env trimer. The improved anti-CD4bs antibodies reported here may provide a helpful complement to current antibody-based protocols for the therapy and prevention of HIV-1 infection.
MeSH term(s)	Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/genetics ; Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Binding Sites ; Binding Sites, Antibody/immunology ; Broadly Neutralizing Antibodies/chemistry ; Broadly Neutralizing Antibodies/genetics ; Broadly Neutralizing Antibodies/immunology ; Broadly Neutralizing Antibodies/therapeutic use ; CD4 Antigens/chemistry ; CD4 Antigens/metabolism ; Epitopes/chemistry ; Epitopes/immunology ; HIV Antibodies/chemistry ; HIV Antibodies/genetics ; HIV Antibodies/immunology ; HIV Antibodies/therapeutic use ; HIV Envelope Protein gp120/chemistry ; HIV Envelope Protein gp120/immunology ; HIV Envelope Protein gp120/metabolism ; HIV Infections/prevention & control ; HIV Infections/therapy ; HIV-1/immunology ; Humans ; Models, Molecular ; Mutation ; Protein Binding ; Protein Engineering ; Protein Multimerization ; Protein Subunits/chemistry
Chemical Substances	Antibodies, Monoclonal ; Broadly Neutralizing Antibodies ; CD4 Antigens ; Epitopes ; HIV Antibodies ; HIV Envelope Protein gp120 ; Protein Subunits ; gp120 protein, Human immunodeficiency virus 1
Language	English
Publishing date	2021-05-24
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, N.I.H., Intramural ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	80174-4
ISSN	1098-5514 ; 0022-538X
ISSN (online)	1098-5514
ISSN	0022-538X
DOI	10.1128/JVI.00159-21
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2

Saadat, Saman / Rikhtegaran-Tehrani, Zahra / Logue, James / Newman, Michelle / Frieman, Matthew B / Harris, Anthony D. / Sajadi, Mohammad M.

medRxiv

Abstract: Coronavirus disease 2019 (COVID-19) vaccine shortages have led some experts and countries to consider untested dosing regimens. We studied antibody responses to a single dose of the Pfizer-BioNTech or Moderna vaccines in healthcare workers (HCW) with ... ...

Abstract	Coronavirus disease 2019 (COVID-19) vaccine shortages have led some experts and countries to consider untested dosing regimens. We studied antibody responses to a single dose of the Pfizer-BioNTech or Moderna vaccines in healthcare workers (HCW) with laboratory-confirmed COVID-19 infection and compared to them to antibody responses of HCW who were IgG negative to SARS-CoV-2 spike protein. HCW with prior COVID-19 showed clear secondary antibody responses to vaccination with IgG spike binding titers rapidly increasing by 7 days and peaking by days 10 and 14 post-vaccination. At all time points tested, HCW with prior COVID-19 infection showed statistically significant higher antibody titers of binding and functional antibody compared to HCW without prior COVID-19 infection (p<.0001for each of the time points tested). In times of vaccine shortage, and until correlates of protection are identified, our findings preliminarily suggest the following strategy as more evidence-based: a) a single dose of vaccine for patients already having had laboratory-confirmed COVID-19; and b) patients who have had laboratory-confirmed COVID-19 can be placed lower on the vaccination priority list.
Keywords	covid19
Language	English
Publishing date	2021-02-01
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2021.01.30.21250843
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Production of a chimeric protein and its potential application in sero-diagnosis of Mycoplasma hominis infection.

Saadat, Saman / Sajadi, Mohammad M / Alikhani, Mohammad Yousef / Rikhtegaran Tehrani, Zahra / Yousefi Mashouf, Rasoul

Journal of microbiological methods

2017 Volume 144, Page(s) 186–191

Abstract: Introduction: Mycoplasma hominis is an opportunistic pathogen of the human genital tract. Detection of antibodies against this organism in human serum or plasma is theoretically unreliable because of high variation in bacterial surface antigens. In this ...

Abstract	Introduction: Mycoplasma hominis is an opportunistic pathogen of the human genital tract. Detection of antibodies against this organism in human serum or plasma is theoretically unreliable because of high variation in bacterial surface antigens. In this study, we applied the bioinformatics tools to design a chimeric protein constructed of specific, conserved and predicted immuno-dominant epitopes from two different membrane proteins, P120 and P80. Material and methods: Linear B-cell epitopes of P120 and P80 were predicted and evaluated by bioinformatics tools and the designed chimeric protein was expressed in Escherichia coli. The chimeric protein, Mh128, was further analyzed in terms of immuno-reactivity by western blotting and enzyme immuno-sorbent assay (ELISA). Results: We found eight specific, conserved and immuno-dominant epitopes within P120 and P80 based on the bioinformatic studies. The constructed chimeric protein showed immuno-reaction in both western-blotting and ELISA tests. Discussion: Because of extensive variation of genomic and antigenic structure, diagnosis of M. hominis infection is difficult. Mh128 as a predicted specific and conserved recombinant protein can be potentially used for sero-diagnosis of M. hominis infection. We plan to develop an immuno-assay based on Mh128 and further evaluate the clinical specificity and sensitivity of the method.
MeSH term(s)	Antibodies, Bacterial/blood ; Antigens, Bacterial/immunology ; Bacterial Proteins/biosynthesis ; Bacterial Proteins/genetics ; Bacterial Proteins/immunology ; Carrier Proteins/biosynthesis ; Carrier Proteins/genetics ; Carrier Proteins/immunology ; Cloning, Molecular ; Computational Biology ; Epitopes, B-Lymphocyte ; Escherichia coli/genetics ; Gene Expression Regulation, Bacterial ; Genes, Bacterial ; Humans ; Membrane Proteins/biosynthesis ; Membrane Proteins/genetics ; Membrane Proteins/immunology ; Mycoplasma Infections/diagnosis ; Mycoplasma Infections/immunology ; Mycoplasma Infections/microbiology ; Mycoplasma hominis/genetics ; Mycoplasma hominis/immunology ; Mycoplasma hominis/metabolism ; Recombinant Fusion Proteins/biosynthesis ; Recombinant Fusion Proteins/immunology
Chemical Substances	Antibodies, Bacterial ; Antigens, Bacterial ; Bacterial Proteins ; Carrier Proteins ; Epitopes, B-Lymphocyte ; Membrane Proteins ; P120 protein, Mycoplasma hominis ; P80 protein, Mycoplasma ; Recombinant Fusion Proteins
Language	English
Publishing date	2017-12-05
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	604916-3
ISSN	1872-8359 ; 0167-7012
ISSN (online)	1872-8359
ISSN	0167-7012
DOI	10.1016/j.mimet.2017.12.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1849: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Maternal transfer of IgA and IgG SARS-CoV-2 specific antibodies transplacentally and via breast milk feeding.

Sajadi, Mohammad M / Shokatpour, Narjes / Purcell, Madeleine / Tehrani, Zahra Rikhtegaran / Lankford, Allison / Bathula, Allison / Campbell, James D / Hammershaimb, Elizabeth Adrianne / Deatrick, Kristopher B / Bor, Casey / Parsell, Dawn M / Dugan, Colleen / Levine, Andrea R / Ramelli, Sabrina C / Chertow, Daniel S / Herr, Daniel L / Saharia, Kapil K / Lewis, George K / Grazioli, Alison

PloS one

2023 Volume 18, Issue 4, Page(s) e0284020

Abstract: Background: Although there have been many studies on antibody responses to SARS-CoV-2 in breast milk, very few have looked at the fate of these in the infant, and whether they are delivered to immunologically relevant sites in infants.: Methods: ... ...

Abstract	Background: Although there have been many studies on antibody responses to SARS-CoV-2 in breast milk, very few have looked at the fate of these in the infant, and whether they are delivered to immunologically relevant sites in infants. Methods: Mother/infant pairs (mothers who breast milk fed and who were SARS-CoV-2 vaccinated before or after delivery) were recruited for this cross-sectional study. Mother blood, mother breast milk, infant blood, infant nasal specimen, and infant stool was tested for IgA and IgG antibodies against SARS-CoV-2 spike trimer. Results: Thirty-one mother/infant pairs were recruited. Breast milk fed infants acquired systemic anti-spike IgG antibodies only if their mothers were vaccinated antepartum (100% Antepartum; 0% Postpartum; P<0.0001). Breast milk fed infants acquired mucosal anti-spike IgG antibodies (in the nose) only if their mothers were vaccinated antepartum (89% Antepartum; 0% Postpartum; P<0.0001). None of the infants in either group had anti-spike IgA in the blood. Surprisingly, 33% of the infants whose mothers were vaccinated antepartum had high titer anti-spike IgA in the nose (33% Antepartum; 0% Postpartum; P = 0.03). Half-life of maternally transferred plasma IgG antibodies in the Antepartum infant cohort was ~70 days. Conclusion: Vaccination antepartum followed by breast milk feeding appears to be the best way to provide systemic and local anti-SARS-CoV-2 antibodies for infants. The presence of high titer SARS-CoV-2-specific IgA in the nose of infants points to the potential importance of breast milk feeding early in life for maternal transfer of mucosal IgA antibodies. Expectant mothers should consider becoming vaccinated antepartum and consider breast milk feeding for optimal transfer of systemic and mucosal antibodies to their infants.
MeSH term(s)	Infant ; Female ; Humans ; Milk, Human ; Cross-Sectional Studies ; COVID-19/prevention & control ; SARS-CoV-2 ; Breast Feeding ; Antibodies, Viral ; Immunoglobulin A ; Immunoglobulin G
Chemical Substances	Antibodies, Viral ; Immunoglobulin A ; Immunoglobulin G
Language	English
Publishing date	2023-04-06
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2267670-3
ISSN	1932-6203 ; 1932-6203
ISSN (online)	1932-6203
ISSN	1932-6203
DOI	10.1371/journal.pone.0284020
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito